This postdoctoral fellowship program in clinical pharmacology provides training in basic and applied human pharmacology for those committed to careers integrating basic and translational research and patient care. The objective of this program is to provide training across the continuum spanning mechanistic, translational, and clinical investigation, with an emphasis on pharmacology and experimental therapeutics, to replenish the dwindling national supply of clinician-investigators. The majority of fellows'time is focused on independent, hypothesis-driven research. The breadth of clinical pharmacology is delivered using a curriculum built upon the institutional NIH K30 Training Program in Human Investigation, including courses in basic and clinical pharmacology, study design, statistics, epidemiology, and ethics, as well as conferences including journal club, ethics, and research seminars. Experiential rotations include the editorial board of the Annals of Internal Medicine, pharmaceutical drug development at Merck Research Laboratories, and human clinical trials in the Jefferson Clinical Research Unit. Trainees customize their education by choosing a range of electives congruent with their career aspirations. These include Institutional Review Board membership, adult PK/PD modeling at Merck, pediatric pharmacometrics at Children's Hospital of Philadelphia, or rotations at the Food and Drug Administration (FDA). Research opportunities are offered by 39 preceptors, representing 10 departments and 3 divisions within the Department of Medicine. These preceptors represent a broad spectrum of disciplines, approaches, and methodologies to ensure a wide selection of training opportunities. Preceptors are selected on the basis of their productive research programs in basic or translational pharmacology funded through extramural mechanisms, success in training competitive investigators, and commitment and ability to train postdoctoral fellows. Programs of these preceptors constitute 13 general areas that span drug discovery, development, utilization, and regulation. Trainees selected from candidates with M.D., Ph.D., or Pharm.D. degrees in areas related to discipline-specific objectives, spend a minimum of 2 years developing core expertise in clinical pharmacology. The program has an established track record of recruiting and retaining highly qualified, diverse trainees who have been uniformly successful in obtaining, and advancing in, academic appointments in clinical pharmacology, leadership positions in the pharmaceutical industry, and regulatory and policy positions as scientists at the FDA.

Public Health Relevance

Advances in the new biology are transforming drug therapy, the most cost-effective component of healthcare. Yet, at this time of scientific opportunity, shortages in specialized workforces limit the discovery and development of drugs and their safe use. To fill that gap, the Jefferson Clinical Pharmacology Fellowship Program is training clinician scientists to translate new discoveries into drugs that revolutionize patient care.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008562-19
Application #
8500325
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PD))
Program Officer
Okita, Richard T
Project Start
1995-07-01
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
19
Fiscal Year
2013
Total Cost
$288,130
Indirect Cost
$20,010
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Marek, Elizabeth; Momper, Jeremiah D; Hines, Ronald N et al. (2016) Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. J Pediatr Pharmacol Ther 21:224-32
Lin, Jieru E; Colon-Gonzalez, Francheska; Blomain, Erik et al. (2016) Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis. Cancer Res 76:339-46
Mari, Elisabeth R; Rasouli, Javad; Ciric, Bogoljub et al. (2016) Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis. Eur J Immunol 46:1783-96
Chand, Saswati; O'Hayer, Kevin; Blanco, Fernando F et al. (2016) The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int J Biol Sci 12:273-82
Moore, J N; Healy, J R; Thoma, B N et al. (2016) A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy. CPT Pharmacometrics Syst Pharmacol 5:495-502
Cantarin, Maria P Martinez; Keith, Scott W; Lin, Zhao et al. (2016) Association of Inflammation prior to Kidney Transplantation with Post-Transplant Diabetes Mellitus. Cardiorenal Med 6:289-300
Kim, G W; Lin, J E; Snook, A E et al. (2016) Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity. Nutr Diabetes 6:e211
Moore, Jason N; Healy, Jason R; Kraft, Walter K (2015) Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol 8:321-34
Rodriguez, Elena; Sakowski, Lauren; Hobson, Grace M et al. (2015) Plp1 gene duplication inhibits airway responsiveness and induces lung inflammation. Pulm Pharmacol Ther 30:22-31
Kozak, Geoffrey; Blanco, Fernando F; Brody, Jonathan R (2015) Novel targets in pancreatic cancer research. Semin Oncol 42:177-87

Showing the most recent 10 out of 60 publications